The role of NIIMBL to advance manufacturing for Cell and Gene Therapy treatments
February 6 – 10, 2022
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.
Funding of $70 million has been committed by NIST for the next 5 years of NIIMBL and this is expected to be more than matched by participants. A key focus will be advancing manufacturing of Gene Therapy and Cell Therapy based products. Discussion is invited regarding the best role for this public-private partnership.
Barry Buckland, "The role of NIIMBL to advance manufacturing for Cell and Gene Therapy treatments" in "Advancing Manufacture of Cell and Gene Therapies VII", Sharon Brownlow, Cell & Gene Therapy Catapult, UK; Sean Palecek, University of Wisconsin, USA; Damian Marshall, Achilles Therapeutics, UK; Fernanda Masri, Cell & Gene Therapy Catapult, UK Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/cellgenetherapies_vii/36